CA2388659A1 - Expression et activite de la phospholipase a2 et utilisation de celle-ci dans le diagnostic, le pronostic, la prevention et le traitement de maladies demyelinisantes ou inflammatoires du systeme nerveux - Google Patents

Expression et activite de la phospholipase a2 et utilisation de celle-ci dans le diagnostic, le pronostic, la prevention et le traitement de maladies demyelinisantes ou inflammatoires du systeme nerveux Download PDF

Info

Publication number
CA2388659A1
CA2388659A1 CA002388659A CA2388659A CA2388659A1 CA 2388659 A1 CA2388659 A1 CA 2388659A1 CA 002388659 A CA002388659 A CA 002388659A CA 2388659 A CA2388659 A CA 2388659A CA 2388659 A1 CA2388659 A1 CA 2388659A1
Authority
CA
Canada
Prior art keywords
phospholipase
leu
ser
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002388659A
Other languages
English (en)
Inventor
Samuel David
Athena Kalyvas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Priority to CA002388659A priority Critical patent/CA2388659A1/fr
Priority to PCT/CA2003/000813 priority patent/WO2003101487A1/fr
Priority to US10/516,241 priority patent/US20060058225A1/en
Priority to EP03727085A priority patent/EP1509247A1/fr
Priority to AU2003233715A priority patent/AU2003233715A1/en
Publication of CA2388659A1 publication Critical patent/CA2388659A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
CA002388659A 2002-05-31 2002-05-31 Expression et activite de la phospholipase a2 et utilisation de celle-ci dans le diagnostic, le pronostic, la prevention et le traitement de maladies demyelinisantes ou inflammatoires du systeme nerveux Abandoned CA2388659A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002388659A CA2388659A1 (fr) 2002-05-31 2002-05-31 Expression et activite de la phospholipase a2 et utilisation de celle-ci dans le diagnostic, le pronostic, la prevention et le traitement de maladies demyelinisantes ou inflammatoires du systeme nerveux
PCT/CA2003/000813 WO2003101487A1 (fr) 2002-05-31 2003-05-30 Utilisation d'inhibiteurs de la phospholipase a2 pour le traitement, la prevention ou le diagnostic des maladies neurales inflammatoires ou demyelinisantes
US10/516,241 US20060058225A1 (en) 2002-05-31 2003-05-30 Used of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease
EP03727085A EP1509247A1 (fr) 2002-05-31 2003-05-30 Utilisation d'inhibiteurs de la phospholipase a2 pour le traitement, la prevention ou le diagnostic des maladies neurales inflammatoires ou demyelinisantes
AU2003233715A AU2003233715A1 (en) 2002-05-31 2003-05-30 Use of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002388659A CA2388659A1 (fr) 2002-05-31 2002-05-31 Expression et activite de la phospholipase a2 et utilisation de celle-ci dans le diagnostic, le pronostic, la prevention et le traitement de maladies demyelinisantes ou inflammatoires du systeme nerveux

Publications (1)

Publication Number Publication Date
CA2388659A1 true CA2388659A1 (fr) 2003-11-30

Family

ID=32111420

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002388659A Abandoned CA2388659A1 (fr) 2002-05-31 2002-05-31 Expression et activite de la phospholipase a2 et utilisation de celle-ci dans le diagnostic, le pronostic, la prevention et le traitement de maladies demyelinisantes ou inflammatoires du systeme nerveux

Country Status (1)

Country Link
CA (1) CA2388659A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112063656A (zh) * 2020-08-28 2020-12-11 中国科学院广州生物医药与健康研究院 Map2k3或Map2k6在提高诱导成体细胞生成多能性干细胞效率中的用途
CN112662645A (zh) * 2021-01-19 2021-04-16 华南理工大学 一种鞘磷脂酶d突变体及其应用
CN114222818A (zh) * 2019-07-02 2022-03-22 基础应用医学研究基金会 cPLA2e诱导剂及其用途
CN114225018A (zh) * 2015-05-08 2022-03-25 生物马林药物股份有限公司 用于治疗cln2疾病的tpp1调配物及方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114225018A (zh) * 2015-05-08 2022-03-25 生物马林药物股份有限公司 用于治疗cln2疾病的tpp1调配物及方法
CN114222818A (zh) * 2019-07-02 2022-03-22 基础应用医学研究基金会 cPLA2e诱导剂及其用途
CN112063656A (zh) * 2020-08-28 2020-12-11 中国科学院广州生物医药与健康研究院 Map2k3或Map2k6在提高诱导成体细胞生成多能性干细胞效率中的用途
CN112662645A (zh) * 2021-01-19 2021-04-16 华南理工大学 一种鞘磷脂酶d突变体及其应用

Similar Documents

Publication Publication Date Title
Gounni et al. Human neutrophils express the high‐affinity receptor for immunoglobulin E (FceRI): role in asthma
Schuh et al. Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models
JP4659736B2 (ja) スクリーニング方法
JP2004522742A (ja) 免疫応答の改変において使用するためのｔｒｅｍ−１スプライス改変体
CA2643048A1 (fr) Traitement de la maladie d'alzheimer avec des inhibiteurs de la fixation de l'apoe au recepteur de l'apoe
Wannick et al. The immunometabolomic interface receptor hydroxycarboxylic acid receptor 2 mediates the therapeutic effects of dimethyl fumarate in autoantibody-induced skin inflammation
US20240139129A1 (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
JP4767019B2 (ja) 動脈硬化の予防・治療用医薬
US20060058225A1 (en) Used of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease
US20190194290A1 (en) Methods for preventing, modulating and/or reducing cardiovascular disease
US20030225011A1 (en) Phospholipase A2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease
CA2758829A1 (fr) Procede de traitement d'une maladie de demyelinisation
CA2388659A1 (fr) Expression et activite de la phospholipase a2 et utilisation de celle-ci dans le diagnostic, le pronostic, la prevention et le traitement de maladies demyelinisantes ou inflammatoires du systeme nerveux
CA2614737A1 (fr) Methodes permettant de controler la destruction des neurones par neuroinflammation et de traiter des maladies presentant une composante inflammatoire liee a la phospholipase a2
US20240182897A1 (en) Oligonucleotide therapeutics and application thereof
JP2009506049A (ja) 不安を治療する方法および抗不安物質を同定する方法
WO2007047950A2 (fr) Utilisation d'inhibiteurs de sumoylation dans le traitement d'une maladie neurodegenerative
EP1600165A1 (fr) Utilisation medicale d'un inhibiteur de mip-3alpha et procede de criblage d'un agent protecteur d'une cellule du cerveau/nerveuse
JP4445291B2 (ja) 新規タンパク質およびそのｄｎａ
WO2022056619A1 (fr) Utilisation de nrg-1bêta1 pour la détection et/ou le traitement de la sclérose en plaques
KR20220061149A (ko) Clec16A 기능장애 또는 손실과 관련된 장애의 치료를 위한 조성물 및 방법
US8110348B2 (en) Methods and compositions for the diagnosis and treatment of schizophrenia
AU2020368759A1 (en) Diabetes therapy targeting abnormal stem cells
EP1705256A1 (fr) Procédé de traitement de résistance à l'insuline et d'états pathologiques caractérisés par une résistance à l'insuline
Uysal et al. AB0162 Protective Effects of Caffeic Acid Phenethyl Ester (CAPE) on Cyclophosphamide Induced Hemorrhagic Cystitis in Rats

Legal Events

Date Code Title Description
FZDE Dead